Source comparison
Kisspeptin for Fertility: IVF vs Natural Ovulation Induction Comparison
Kisspeptin for fertility applications differ significantly depending on whether the goal is IVF oocyte triggering or natural ovulation induction. The dosing, monitoring, and expected outcomes vary across these two clinical contexts. IVF Oocyte Trigger 9.6–12.8
This comparison does not assign a generated winner or score.
- Kisspeptin for fertility applications differ significantly depending on whether the goal is IVF oocyte triggering or natural ovulation induction. The dosing, monitoring, and expected outcomes vary across these two clinical contexts.
- IVF Oocyte Trigger
- 9.6–12.8 nmol/kg SC single dose, 36h pre-retrieval
- Number of mature oocytes retrieved
- 0–2% (vs 10–15% with hCG)
- 30–44% per transfer (lower without luteal rescue hCG)
- High ovarian reserve, PCOS, prior OHSS history
- Safer than hCG for maturation trigger but requires luteal phase support. Ideal for OHSS-risk patients
- Hypothalamic Amenorrhea
- 6.4 nmol/kg SC twice weekly × 8–12 weeks
- Ovulation (confirmed by mid-luteal progesterone >10 ng/mL)
- <1%
- 25–40% per cycle (natural conception)
- Functional hypothalamic amenorrhea, stress/exercise-induced anovulation
- Restores physiological ovulation in patients resistant to clomiphene. Requires cycle monitoring
- Hypogonadotropic Hypogonadism
- 0.1–0.3 nmol/kg/h continuous SC infusion (kisspeptin-10)
- Sustained LH pulsatility and follicle growth >14mm
- 40–60% per cycle (limited data)
- Congenital or idiopathic hypogonadotropic hypogonadism
- Mimics endogenous GnRH pulses but requires pump device. Experimental approach
- PCOS Ovulation Induction
- 3.2–6.4 nmol/kg SC weekly × 4–8 weeks
- Monoovulation (single dominant follicle ≥18mm)
- 2–5%
- 30–50% per cycle (limited trials)
- PCOS with anovulation, clomiphene resistance
- May reduce multifollicular development vs gonadotropins. Data still emerging
- The key distinction: kisspeptin for fertility in IVF replaces hCG as a single-dose trigger to complete oocyte maturation in already-stimulated ovaries, while ovulation induction protocols use repeated kisspeptin doses to drive the entire follicular phase from baseline. The former prioritizes safety (avoiding OHSS), while the latter prioritizes physiological hormone dynamics (restoring natural GnRH pulsatility). Neither application is FDA-approved. All current use occurs within clinical trials or off-label research contexts.